Open an account

BridgeBio Oncology Therapeutics

BBOT · NASDAQ

$2.72−$0.13 (−4.56%)TodayMarket closed ·
Prev close $2.85

About BBOT

Bridgebio Oncology Therapeutics, Inc. engages in developing bioavailable small molecule inhibitors. The company is headquartered in South San Francisco, California. The company went IPO on 2024-02-09. The firm is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.

Employees
0
Headquarters
South San Francisco, California
Listed
Feb 9, 2024
Sector
Health Care
Industry
Biotechnology
Website
bbotx.com

BBOT key statistics

Market cap
218.07M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
557.67K
Volume
660.94K
Open price
$2.85
High today
$2.98
Low today
$2.70
52 Week high
$14.87
52 Week low
$2.79

BridgeBio Oncology Therapeutics (BBOT) at a glance

BridgeBio Oncology Therapeutics (BBOT) last traded at $2.72, with a market cap of 218.07M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.70 and $2.98. The current price is 0.7% above the day's low and 8.7% below its high.

Volume so far is 660.94K shares, in line with the average of 557.67K shares a day.

Over the past year BridgeBio Oncology Therapeutics has ranged from $2.79 to $14.87, and now sits -1% of the way up that range.

BridgeBio Oncology Therapeutics met or beat analyst EPS estimates in 2 of the last 4 quarters. In Q2 FY26 it reported -$0.71 per share against an estimate of -$0.5766.

The average analyst price target is $22.33, 720.8% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 12 analystsAvg $22.33
Low
$15.15
Now
$2.72
High
$30.45

BBOT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 4 quarters, by 4.3% on average.

  1. Q3 FY25: reported -$1.03 per share against an estimate of -$0.3976
  2. Q4 FY25: reported -$0.49 per share against an estimate of -$0.5275
  3. Q1 FY26: reported -$0.53 per share against an estimate of -$0.5375
  4. Q2 FY26: reported -$0.71 per share against an estimate of -$0.5766

BBOT news

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseGlobe Newswire

    BBOT to Participate in Upcoming Investor Healthcare Conferences

  • Press releaseGlobe Newswire

    BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Press releaseGlobe Newswire

    BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

  • Press releaseGlobe Newswire

    BBOT to Participate in Upcoming Investor Healthcare Conferences

  • Press releaseGlobe Newswire

    BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

  • Press releaseGlobe Newswire

    BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference

Similar companies

Companies in the same industry as BridgeBio Oncology Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.